BR100 Increased By (0.67%)
BR30 Increased By (0.87%)
KSE100 Increased By (0.52%)
KSE30 Increased By (0.56%)
BECO 6.06 Increased By ▲ 0.29 (5.03%)
BML 53.10 Increased By ▲ 0.10 (0.19%)
BOP 34.23 Increased By ▲ 0.24 (0.71%)
CNERGY 8.18 Increased By ▲ 0.07 (0.86%)
DCL 12.44 Increased By ▲ 0.24 (1.97%)
FCCL 53.34 Increased By ▲ 0.51 (0.97%)
FCSC 5.20 Increased By ▲ 0.13 (2.56%)
FFL 18.10 Increased By ▲ 0.15 (0.84%)
FNEL 1.31 Increased By ▲ 0.02 (1.55%)
HUMNL 10.95 Increased By ▲ 0.07 (0.64%)
KEL 8.06 Increased By ▲ 0.04 (0.5%)
KOSM 5.50 Decreased By ▼ -0.02 (-0.36%)
MLCF 87.33 Increased By ▲ 0.82 (0.95%)
NBP 186.25 Increased By ▲ 1.09 (0.59%)
PACE 10.78 Increased By ▲ 0.20 (1.89%)
PAEL 39.68 Increased By ▲ 0.26 (0.66%)
PIAHCLA 26.10 Decreased By ▼ -0.12 (-0.46%)
PIBTL 16.85 Increased By ▲ 0.18 (1.08%)
PPL 229.74 Increased By ▲ 1.56 (0.68%)
PRL 34.90 Increased By ▲ 0.22 (0.63%)
PTC 67.38 Increased By ▲ 2.05 (3.14%)
SEARL 90.87 Increased By ▲ 0.74 (0.82%)
SSGC 26.84 Increased By ▲ 0.24 (0.9%)
TELE 8.65 Increased By ▲ 0.37 (4.47%)
THCCL 59.20 Increased By ▲ 0.70 (1.2%)
TPLP 8.43 Increased By ▲ 0.21 (2.55%)
TREET 24.70 Increased By ▲ 0.17 (0.69%)
TRG 69.99 Increased By ▲ 0.28 (0.4%)
WAVES 10.04 Increased By ▲ 0.10 (1.01%)
WTL 1.29 Increased By ▲ 0.01 (0.78%)

KARACHI: In violation of the Sindh Drug Rules, pharmaceutical manufacturers and distributors have expressed dismay over not being invited to an upcoming scheduled meeting of the Sindh Quality Control Board (SCQB), prompting concerns over transparency and regulatory fairness, Business Recorder has learnt.

In a formal letter to the Sindh Health Department, PCDA Secretary General M Asim Jamil expressed disappointment that the association, despite being the only registered trade body representing chemists, druggists, importers, and distributors, was not invited to participate in the Board’s scheduled meeting.

He emphasised that under the Sindh Drug Rules (Amended) 2010, relevant trade bodies must be consulted on matters related to pharmaceutical regulation.

“It has come to our attention that meetings of the SCQB are being scheduled, but PCDA has not been invited despite being a key stakeholder,” the letter read. “This raises concerns regarding transparency and fairness in the Board’s decision-making.”

PCDA also noted that the PPMA, which represents local drug manufacturers, had similarly been excluded from attending as an observer, further intensifying industry apprehensions about the lack of representation in regulatory proceedings that directly impact their operations.

Calling for immediate rectification, PCDA urged the Health Secretary to ensure the inclusion of both associations in future SCQB meetings to uphold fair practices and regulatory clarity.

Copyright Business Recorder, 2025

Comments

Comments are closed for this article.